anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIMS: A nutritional status is related to the length of hospitalization and in-hospital mortality of patients with heart failure (HF). The aim of this study is to assess the prognostic impact of nutritional status and body mass index (BMI) on in-hospital mortality among patients with HF relative to their sex.
METHODS AND RESULTS: We conducted a retrospective study and analysis of 809 medical records of patients admitted to the Institute of Heart Disease of the University Clinical Hospital in Wroclaw (Poland). Women were statistically significantly older than men (74.67 ± 11.15 vs. 66.76 ± 17.78; P < 0.001). In unadjusted model, significant predictors of the odds of in-hospital mortality for men were underweight (OR = 14.81, P = 0.001) and the risk of malnutrition (OR = 8.979, P < 0.001). In the case of women, none of the traits analysed was significant. In age-adjusted model, significant independent predictors of the odds of in-hospital mortality in the case of men were BMI < 18.5 (OR = 15.423, P = 0.001) and risk of malnutrition (OR = 5.557, P = 0.002). In the case of women, none of the nutritional status traits analysed were significant. In multivariable-adjusted model in men, significant independent predictors of the odds of in-hospital mortality were BMI < 18.5 (OR = 15.978, P = 0.007) compared with having normal body weight and the risk of malnutrition (OR = 4.686, P = 0.015). In the case of women, none of the nutritional status traits analysed were significant.
CONCLUSION: Both underweight and the risk of malnutrition are direct predictors of the odds of in-hospital mortality in men, but not in women. The study did not find a relationship between nutritional status and in-hospital mortality in women.
The present invention relates to an anti-aging functional cosmetic composition containing a cell-permeable carbonyl reductase fusion protein and pozzolan. Human carbonyl reductase 1 (CBR1) is a member of NADH-dependent short-chain dehydrogenase/reductase superfamily, and this superfamily is known to play a key role in neuronal survival through the antioxidant properties. The inventors have tested whether the protective effect in the inflammation and cell death induced by LPS or hydrogen peroxide is shown by producing a cell-permeable PEP-1-CBR1 fusion protein and transmitting the same into cells or tissues. As a result, the PEP-1-CBR1 fusion protein has exhibited significant cell protection activity against the inflammation and cell death induced by hydrogen peroxide by effectively permeating into HaCaT cells. Moreover, it was found to have more excellent protection effect on the mechanism of cell death in the case that pozzolan is pre-processed. The present invention has revealed that the PEP-1-CBR1 fusion protein and the pozzolan can be used for antioxidant functional cosmetics.
The present invention relates to a nanocomposite comprising: a nano drug delivery system; and a ginseng extract or ginsenoside separated therefrom, and a method for producing the same. The nanocomposite can be used for the prevention or treatment of cancer and inflammatory diseases. The production time of the nanocomposite of the present invention is significantly reduced compared to conventional metal nanoparticles, and metal nanocomposites having a uniform size can be produced without the addition of a separate reducing agent or stabilizer. Also, the nanocomposite of the present invention has a high solubility in water and a high ability to target cancer cells, and thus is advantageous to be developed as a drug. In addition, the nanocomposite of the present invention exhibits high anti-cancer activity, anti-inflammatory activity, etc., and thus can be usefully utilized in the prevention and treatment of cancer and inflammatory diseases. Furthermore, the nanocomposite of the present invention has antibacterial activity, biofilm decomposition activity and anticoagulant activity, and thus can be utilized in various business fields.
A colored ceramic powder is compacted into a green state body via isostatic or biaxial pressing. The colored ceramic powder is produced from a mixture of a coloring solution consisting of metallic salts that is introduced to a ceramic slurry and subsequently dried. A coloring solution may comprise for example a metallic salt, a solvent, an organic solvent such as derivatives of propylene oxides, and an acid. Such a coloring solution can be used as a coloring agent for a ceramic body. The solution is thoroughly mixed with the ceramic slurry. Following the addition of the coloring agent, a binder can be added to the color slip. The amount of binder added can be anywhere from 0.5% to 10% by weight. Such a binder can be organic based, alcohol based, or acrylic based. Once all the constituents are thoroughly mixed to a homogeneous state, the slip is dried. The drying process can range from a conventional means to a more sophisticated methods which use spray drying equipment.. The slip can be subjected to a heating process over a range of temperatures such that all residual moisture is removed, leaving only a dried press-able powder. The dried powder can then be subjected to an isostatic or biaxial press manufacturing process to create a green state ceramic body. Once pressed, the ceramic body can be subjected to a sintering process. After final sinter, the resulting ceramic body possesses an innate color that is homogenous throughout its composition. The method is especially useful for coloring zirconia dental restorations.
The present invention relates to a drug delivery field, and particularly, to a cationic liposome-based drug delivery field. In an embodiment, the present invention provides a method for preparing ligand-targeted (for instance, antibody- or antibody fragment-targeted) liposomes which are useful to deliver liposomes to a tumor including brain tumor. In an embodiment, the liposomes are delivered by delivering temozolomide across a blood-brain barrier to treat primary or metastatic brain tumor. Additional cancer which can be treated with liposomes includes neuroendocrine tumor, melanoma, prostate cancer, head and neck cancer, ovarian cancer, lung cancer, liver cancer, breast cancer, urinogenital cancer, stomach cancer, colorectal cancer, cervical cancer, liposarcoma, rhabdomyosarcoma, choriocarcinoma, pancreatic cancer, retinoblastoma and other types of cancer. In another embodiment, the liposomes deliver melphalan to treat multiple myeloma, other blood tumors, or other solid tumors. In still another embodiment, the liposomes may deliver other drugs including atropine to treat organophosphorus poisoning. [Reference numerals] (AA) Cell viability (% of control); (BB) Free TMZ; (CC) Concentration of TMZ (쨉M)
BACKGROUND: Many prehospital emergency patients receive suboptimal treatment for their moderate to severe pain. Various factors may contribute. We aim to systematically review literature pertaining to prehospital emergency adult patients with acute pain and the pain-reducing effects, adverse events (AEs), and safety issues associated with inhaled analgetic agents compared with other prehospital analgesic agents.
METHODS: As part of an initiative from the Scandinavian Society of Anaesthesia and Intensive Care Medicine, we conducted a systematic review (PROSPERO CRD42018114399), applying the PRISMA guidelines, Grading of Recommendations Assessment, Development, and Evaluation (GRADE), and Cochrane methods, searching the Cochrane Library, Epistemonikos, Centre for Reviews and Dissemination, PubMed, and EMBASE databases (updated March 2024). Inclusion criteria were the use of inhaled analgesic agents in adult patients with acute pain in the prehospital emergency care setting. All steps were performed by minimum of two individual researchers. The primary outcome was pain reduction; secondary outcomes were speed of onset, duration of effect, and relevant AEs.
RESULTS: We included seven studies (56,535 patients in total) that compared inhaled agents (methoxyflurane [MF] and nitrous oxide [N2O]) to other drugs or placebo. Study designs were randomized controlled trial (1; n = 60), randomized non-blinded study (1; n = 343), and randomized open-label study (1; n = 270). The remaining were prospective or retrospective observational studies. The evidence according to GRADE was of low or very low quality. No combined meta-analysis was possible. N2O may reduce pain compared to placebo, but not compared to intravenous (IV) paracetamol, and may be less effective compared to morphine and MF. MF may reduce pain compared to paracetamol, ketoprofen, tramadol, and fentanyl. Both agents may be associated with marked but primarily mild AEs.
CONCLUSION: We found low-quality evidence suggesting that both MF and N2O are safe and may have a role in the management of pain in the prehospital setting. There is low-quality evidence to support MF as a short-acting single analgesic or as a bridge to IV access and the administration of other analgesics. There may be occupational health issues regarding the prehospital use of N2O.
This is an optional dose cohort that the SRC will determine depending on the results of Cohorts 1 and 2, including the proposed dose level. Potential subjects in this cohort will also follow the same dosing scheme as those for Cohorts 1 and 2.
PURPOSE:To provide an aqueous solution of diisopropyl.1,3-dithiol-2-ylidene malonate which is stable to the long-term storage or dilution, by solubilizing the above compound with a nonionic surface active agent, propylene glycol and a specific stabilizer. CONSTITUTION:(A) Diisopropyl.1,3-dithiol-2-ylidene malonate which is under development as a remedy for chronic hepatic diseases and hepatocirrhosis, is solubilized with (B) a nonionic surface active agent such as hydrogenated castor oil ethylene oxide adduct, (C) propylene glycol and (D) a stabilizer derived from vitamin E or its derivative, a neutral oil (8-20C straight-chain saturated or unsaturated fatty acid triglyceride), lecithin, a (preferably 7-10C) higher alcohol and cholesterol. The amounts of the components B, C and D are preferably 1- 5pts.wt., 1-4pts.wt. and 0.03-0.5pts.wt. per 1pt.wt. of the component A.
Usual care. Stroke patients admitted to the ED during the 3-month baseline inclusion period.
Participants with end-stage renal disease (requiring hemodialysis 3 times per week for at least 3 months before screening; eGFR will not be calculated) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
The Drug Counseling intervention consists of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
Extra-articular manifestations (EAM), which are associated with rheumatoid arthritis (RA), affect the quality of life of patients and are one of the critical causes of early mortality. This study was aimed at investigating whether Bacillus subtilis NMCC-path-14 (1 × 108 CFU/animal/day) could serve as a valuable therapeutic agent in managing EAM using complete Freund's adjuvant (CFA) induced arthritis during acute and sub-acute phases. Arthritis was induced using intra-dermal administration of CFA in the right hind paw of mice on day 1. Dexamethasone (Dexa) (5 mg/kg/day/animal) was used as a standard treatment. Animals in Dexa and Bacillus subtilis concurrent treatment (BS-CT) received treatments on day 1. The Bacillus subtilis pre-treatment (BS-PT) group received a probiotic dose 7 days before arthritis induction. Parameters like body weight, relative organ weight, colon length, hematology, serum biochemistry, antioxidant capacity, and histopathology of liver, kidney, spleen, colon, stress-related behavioral changes, and cortisol levels were evaluated on days 7 (acute) and 14 (sub-acute). Dexa failed to manage the EAM in arthritic mice and instead exacerbated them. On the other hand, B. subtilis NMCC-path-14 significantly declined EAM with no notable side effects, highlighting its safety and effectiveness. The current data show that B. subtilis NMCC-path-14 may be an alternative option for arthritis treatment that can reduce systemic symptoms associated with arthritis. More studies are required to comprehend the underlying mechanisms of mitigating the EAM by B. subtilis NMCC-path-14.
This disclosure provides novel compositions comprising an inorganic and organic compound, which provides a means for the indirect attachment of a reactive species, such as an organic reactive molecule, within a binder polymer matrix. Such compositions provide a hydrophilic nanoscale domain that is uniformly dispersed within the polymer matrix. The nanoscale domain comprises inorganic particles having a nanoscale dimension. Such compositions can enhance the performance potential of the re-active species within the polymer material. The polymer composite that results from the introduction of such reactive species into a polymer matrix provides a self-decontaminating feature. The reactive species include those that are capable of associating with a halogen to form a complex that is active in decontamination of chemical or biological agents.
1,223,220. Decorative cosmetics. L'OREAL. 4 July, 1969 [11 July, 1968], No. 33961/69. Heading A5B. A decorative cosmetics product (such as a lipstick) comprising at least one wax, vegetable or mineral oil, lanolin or a fatty acid, alcohol or ester derived from lanolin, as base, 4 to 10% by weight of at least one organophilic suspending agent and 3 to 15‹C by weight based on the weight of the product, of metallic platelets having an average particle size of from 100 to 150 microns may be prepared by mixing the ingredients so as to render the final mixture homogeneous. The product may also contain a coloured pigment and/or a surface-active agent such as a polyoxyethyleneated, polyoxypropylenated or polyglycerolated fatty alcohol, e.g. polyglycerolated lanolin. Preferably the platelets are made of aluminium, have angular geometric shapes and are coated with a coloured or colourless varnish. Preferably the suspending agent is thixotropic e.g. bentonite and/or montmorillonite which has been rendered organophilic such as a quaternary ammonium salt of a montmorillonite clay.
Renal cell carcinoma (RCC) ranks as a prevalent malignant neoplasm, with clear cell renal cell carcinoma (ccRCC, also known as KIRC) accounting for approximately 75% of all RCC cases. The farnesoid X receptor (FXR, encoded by NR1H4), functioning as a nuclear receptor, plays a crucial role in regulating gene transcription. Although the involvement of FXR in tumors of the digestive system and in acute kidney injury has been extensively studied, its specific role in the pathogenesis of ccRCC has yet to be thoroughly investigated. Consequently, the objective of our current investigation is to uncover the functional roles of FXR in ccRCC. In this study, plasmids for the overexpression of FXR were constructed, and small interfering RNA (siRNA) constructs were designed. Dual-luciferase reporter assays confirmed a direct binding interaction between FXR and the promoter of the matrix metalloproteinase 7 (MMP-7) gene. Additionally, a mouse xenograft model elucidated the regulatory effect of FXR on MMP-7 in the context of tumor growth. This study elucidates how FXR regulates the promotion of ccRCC through the MMP-7-mediated EMT pathway. Interestingly, FXR is typically regarded as a tumor suppressor gene that affects gastrointestinal tumors, providing a potential new therapeutic direction for ccRCC.
Breast cancer is one of the most common types of cancer, representing 15 % of all new cancer cases in the United States. Approximately 12.4 % of all women will be diagnosed with breast cancer during their lifetime. In the past decades, a decrease in cancer-related mortality is evident as a result of early screening and improved therapeutic options. Nonetheless, breast cancer survivors face long-term treatment side effects, with cardiotoxicity being the most significant one, which lead to increased morbidity and mortality. Breast cancer patients are particularly susceptible to cancer therapeutics-related cardiac dysfunction (CTRCD) as treatment regimens include cardiotoxic drugs, primarily anthracyclines and anti-human epidermal growth factor receptor 2 (anti-HER2) agents (recombinant humanized monoclonal antibodies directed against HER2 such as trastuzumab and pertuzumab). Cardiotoxicity is the most common dose-limiting toxicity associated with trastuzumab. Discontinuation of trastuzumab however, can lead to worse cancer outcomes. There have been case reports, registry-based, retrospective cohort-based and mechanistic studies suggesting the cardioprotective potential of SGLT2i in CTRCD. It is not known whether SGLT2i can prevent the development of incident HF or reduce the risk of HF in patients receiving trastuzumab with or without other concurrent anti-HER2 agent or sequential anthracycline for treatment of HER2 positive breast cancer. Based on these, there is now a call for randomized controlled trials to be performed in this patient cohort to advise guideline-directed therapy for CTRCD, which will in turn also provide detailed safety information and improve cancer and cardiovascular outcomes.
This is a 2-part, open-label, single-arm, dose escalation study. Part I will define the Maximum Tolerated Dose (MTD) and optimal dose of SPI-1620 and evaluate its PK and PD properties. Eligible patients will receive SPI-1620 delivered intravenously over one minute on Days 1, 8 and 15. On Day 8 patients will undergo a series of four H215O PET Blood Flow (BF) scans which will be used to assess alterations in BF induced by SPI-1620 in tumor and non-tumor ROIs (Region of Interest). Fifteen minutes after receiving SPI-1620 on Day 15, patients will receive docetaxel, 60 mg/m2, administered by infusion over 1 hour. Accelerated dose escalation of SPI-1620 will be employed: one patient will be treated at each dose level with 100% increases between dose levels. If any grade 2 or higher, related AE occurs, the trial will revert to 3-patient cohorts with 40% dose escalation between groups. There will be no intrapatient dose escalation. Dose escalation will continue until there is either no further increase in tumor blood flow as assessed by H215O PET scan, or until significant toxicity is observed. Once the MTD for SPI-1620 is identified, a second phase of the study will focus on dose escalation of docetaxel studied in groups of 3-6 patients. This part of the study will assess the safety and tolerability of increasing doses of docetaxel administered with the optimal dose of SPI 1620 defined in Part I. If 60 mg/m 2 was tolerated in Part I then up to six patients in Part II will receive docetaxel at a dose of 80 mg/m2 once every 3 weeks. If this is tolerated the next group of patients will receive docetaxel 100 mg/m2 once every 3 weeks.
Neutrophils rapidly infiltrate sites of infection and possess several microbicidal strategies, such as neutrophil extracellular traps release and phagocytosis. Enhanced neutrophil infiltration is associated with higher susceptibility to Leishmania infection, but neutrophil effector response contribution to this phenotype is uncertain. Here, we show that neutrophils from susceptible BALB/c mice (B/c) produce more NETs in response to Leishmania major than those from resistant C57BL/6 mice (B6), which are more phagocytic. The absence of neutrophil elastase contributes to phagocytosis regulation. Microarray analysis shows enrichment of genes involved in NET formation (mpo, pi3kcg, il1b) in B/c, while B6 shows upregulation of genes involved in phagocytosis and cell death (Arhgap12, casp9, mlkl, FasL). scRNA-seq in L. major-infected B6 showed heterogeneity in the pool of intralesional neutrophils, and we identified the N1 subset as the putative subpopulation involved with phagocytosis. In vivo, imaging validates NET formation in infected B/c ears where NETing neutrophils were mainly uninfected cells. NET digestion in vivo augmented parasite lymphatic drainage. Hence, a balance between NET formation and phagocytosis in neutrophils may contribute to the divergent phenotype observed in these mice.
A method for medical service management and related devices are provided. The method is applicable to a blockchain node device and includes the following. An appointment request from a user is received, where the appointment request includes a user identity. Medical service information is recommended according to the appointment request. A medical service scheme is determined according to the medical service information. A medical-fee payment contract is generated according to the medical service scheme. In response to receiving from the user a confirmation message of the medical-fee payment contract, according to the medical-fee payment contract, medical fee is transferred from a digital wallet of the user to at least one digital wallet of at least one related party of the medical service scheme. A device corresponding to the method is further provided.
BACKGROUND: The prevalence of pre-frailty is notably high among maintenance hemodialysis (MHD) patients. Pre-frailty, an early and reversible condition between non-frailty and frailty, can lead to adverse outcomes such as increased unplanned hospital admissions and a higher risk of other chronic diseases. Early identification and intervention of pre-frailty in MHD patients are crucial. This study aimed to establish a simple and effective model for screening and identifying MHD patients at high risk of pre-frailty by using 50 kHz-Whole Body Phase Angle (PhA) measured by bioelectrical impedance analysis (BIA), hand grip strength (HGS), the Five-Times-Sit-to-Stand Test (FTSST), and laboratory parameters, with a specific focus on gender differences.
METHODS: This prospective cross-sectional study was conducted from September to December 2023 at the Wenjiang Hemodialysis Center in the Department of Nephrology, West China Hospital, Sichuan University, Chengdu, China. A total of 244 MHD patients, including 130 males and 114 females, were enrolled, comprising 128 non-frail and 116 pre-frail individuals. Data were collected prospectively, including demographic information, physical measurements, and laboratory test results. All participants provided informed consent before enrollment. The FRAIL scale (FS) was used to assess pre-frailty in MHD patients. Grip strength was measured using an electronic grip strength tester, physical function was assessed using the Five-Times-Sit-to-Stand Test, and whole-body phase angle was measured using the InBody S10 device.
RESULTS: A total of 244 MHD patients with a mean age of 53.75 ± 0.90 years were enrolled, including 130 males with a mean age of 54.12 ± 1.26 years and 114 females with a mean age of 53.32 ± 1.29 years. ROC curve analysis showed that in male patients, the AUC of PhA for predicting pre-frailty was 0.919, with a sensitivity of 94.5% and specificity of 91.3%, and a cutoff value of 6.05°; in female patients, the AUC of PhA was 0.870, with a sensitivity of 70.5% and specificity of 90.6%, and a cutoff value of 5.25°. The AUC of FTSST for screening pre-frailty in male patients was 0.827, with a sensitivity of 62.3% and specificity of 96.2%, and a cutoff value of 12.95 s; in female patients, the AUC of FTSST was 0.784, with a sensitivity of 67.3% and specificity of 84.0%, and a cutoff value of 12.95 s. Additionally, in male patients, the combination of PhA and FTSST resulted in an AUC of 0.930, with a sensitivity of 96.4% and specificity of 81.3%; in female patients, the AUC was 0.911, with a sensitivity of 78.7% and specificity of 92.5%.
CONCLUSION: PhA measured by BIA, in combination with the Five-Times-Sit-to-Stand Test, serves as an effective screening tool and predictor of pre-frailty in MHD patients. The combination of PhA and FTSST shows enhanced diagnostic value in female patients, while PhA alone is sufficient for predicting pre-frailty in male patients.
TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2100051111), registered on 2021-09-13.